Continuous therapy with intravenous prostacyclin for primary pulmonary hypertension: A bridge to heart-lung transplantation

M. R. Kramer, S. Fucks, Z. Simon, N. Berkman

Research output: Contribution to journalArticlepeer-review

Abstract

Primary pulmonary hypertension (PPH) continues to be a major problem. Vasodilator therapy has been of variable success in selected patients. Recently, with the introduction of prostacyclin (Prostaglandin I2, epoprostenon) as a potent vasodilator, several reports have shown a positive effect in primary pulmonary hypertension. We report here two patients with PPH who responded favorably to continuous intravenous therapy with prostacyclin. Both patients responded with a reduction in pulmonary vascular resistance, increase in cardiac output and dramatic improvement of right heart failure. Although therapy with prostacyclin is extremely expensive it may be used as a bridge to heart-lung transplantation in patients with end-stage PPH who do not respond adequately to alternative therapy.

Original languageEnglish
Pages (from-to)613-616
Number of pages4
JournalIsrael Journal of Medical Sciences
Volume29
Issue number10
StatePublished - 1993
Externally publishedYes

Keywords

  • Heart-lung transplantation
  • Primary pulmonary hypertension
  • Prostacyclin

Fingerprint

Dive into the research topics of 'Continuous therapy with intravenous prostacyclin for primary pulmonary hypertension: A bridge to heart-lung transplantation'. Together they form a unique fingerprint.

Cite this